Navigation Links
Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
Date:2/24/2011

THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA (denosumab) to Zometa® (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVA's superiority compared to Zometa in preventing SREs.

XGEVA was approved by the U.S. Food and Drug Administration (FDA) on Nov. 18, 2010 for the prevention of SREs in patients with bone metastases from solid tumors, including prostate cancer.  XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.  XGEVA, the first and only FDA-approved RANK Ligand inhibitor, is the first new treatment for advanced cancer patients with bone metastases in nearly a decade.  

"Bone metastases represent a significant risk for advanced prostate cancer patients due to the potential for serious bone complications such as fracture and spinal cord compression," said Karim Fizazi, M.D., Ph.D., head of the department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France. "The results of this study show that XGEVA prevents these serious bone complications more effectively than Zometa without the requirement of intravenous infusion and without the need for dose adjustment for renal function.  XGEVA represents an important new treatment option for advanced prostate cancer patients with bone metastases."

Bone metastases, the spread of cancer to the bones, are a serious concern for patients with advanced cancer and present a considerable burden to the healthcare system. Weakened bones due to metastases can lead to fractures and compression of the spinal cord and necessi
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... - No one has covered cath labs ... - Primary research covering 700 angioplasty centres ... states & regions; hospital chains; govt. & pvt. hospitals ... stent market in India , which ... and Bio-Absorbable Stent (BVS), was valued above $400 million ...
(Date:5/4/2015)... Ill. , May 4, 2015  Landauer, Inc. ... and environmental radiation measurement and monitoring, outsourced medical physics ... it will release financial results for the fiscal second ... 11, 2015. The Company will also ... 11, 2015 at 4:00 p.m. Central Time (5:00 p.m. ...
(Date:5/4/2015)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... XIAFLEX ® (collagenase clostridium histolyticum or CCH) in ... announce its first quarter 2015 financial results after the ... 11, 2015 and will host a conference call and ... May 12, 2015.  In order to ...
Breaking Medicine Technology:India Coronary Stent Market to be Tripled by 2021 2India Coronary Stent Market to be Tripled by 2021 3India Coronary Stent Market to be Tripled by 2021 4Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Second Quarter 2015 Results And Conference Call 2BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... TSX: BMR, TORONTO, July 10, 2007 /PRNewswire-FirstCall/ ... to the,development and commercialization of cancer therapies, ... independent team in,Basel, Switzerland validates tenascin as ... new treatments for glioblastoma,multiforme (GBM). , The ...
... 2007 - BusinessWeek,published an article on July ... companies to be first to bring to,market ... angiogenesis therapies are being pursued by,Sanofi-Aventis, Boston ... highlights a very promising new biological,therapy for ...
Cached Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease 2
(Date:5/5/2015)... (PRWEB) May 05, 2015 May is National ... the Institute for Better Bone Health . Founded by ... aims to educate both consumers and physicians about the latest ... of bone health. , According to a study recently published ... total Americans are affected by osteoporosis and low bone mass. ...
(Date:5/5/2015)... May 05, 2015 Care ... guidebook called “Medicare Breakeven Challenges? A Model ... includes:, ,     Formulas for two ... measuring but should be ,     A ... “white space” and ensures sustained efficient operations ...
(Date:5/5/2015)... After conducting a nationwide executive search ... West Holt Medical Services in Atkinson, Neb., ... skilled healthcare executive with more than 10 years of ... June 1st. , “Brad brings a proven track record ... and success in building strong relationships with physicians,” said ...
(Date:5/5/2015)... McMunn Associates , a leader in ... today that it has officially launched a new web ... president and founder, Larry McMunn, the new web site ... for growth and expansion for the next several decades. ... years by building close, personal relationships with clients. McMunn ...
(Date:5/5/2015)... 2015 Swiftwick, a leading athletic performance ... a presenting sponsor. The partnership launched May 3, 2015, ... The COLORDASH is an innovative, untimed community race where ... by the COLORDASH. At each kilometer of the race, ... “let the color move them.” , The organization demonstrates ...
Breaking Medicine News(10 mins):Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 3Health News:Care Logistics Publishes a New Hospital Guidebook for Achieving Medicare Breakeven 2Health News:West Holt Medical Services Hires New Chief Executive Officer 2Health News:West Holt Medical Services Hires New Chief Executive Officer 3Health News:McMunn Associates Launches New Corporate Branding with New Website 2Health News:Swiftwick Partners with COLORDASH as Presenting Sponsor 2
... in mice pinpoints role of gene mutation in triggering ... Scientists believe they may have found the biological trigger ... In the March 12 issue of Neuron ... increased levels of the neurotransmitter glutamate in the brain ...
... 11 The Coalition for Ethical Imaging (CEI), a ... practices in Texas, has announced its support for Senate ... companion bill in the House, House Bill 2599 by ... imaging patient care and safety in the state of ...
... a leading provider of the flu shot across the nation, has ... ... (Vocus) March 11, 2009-- Nationwide Medical/Surgical, a leading provider of ... a preservative-free flu vaccine ., , ,The influenza virus, more ...
... Calif., March 11 MAP Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 29th Annual Health Care Conference on ... MA.A live webcast of the presentation will be available on ... http://www.mappharma.com . A replay will also be available within 24 ...
... have pinpointed a cellular pathway that determines whether ... their development. When this pathway, known as PI3K ... and proliferate independent of the amount of food ... tumors respond to dietary restrictiondefined as food consumption ...
... changing needs of Philadelphia seniorsPHILADELPHIA, March 11 ... senior care services, NewCourtland has announced plans to ... homes to AristaCare Health Services. The transaction will ... living options and community-based programming for seniors. AristaCare ...
Cached Medicine News:Health News:Clues Found to Brain Mechanism Behind Migraines 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3Health News:Nationwide Medical/Surgical Announces Preservative Free Flu Vaccine Available 2Health News:Cell pathway on overdrive prevents cancer response to dietary restriction 2Health News:Cell pathway on overdrive prevents cancer response to dietary restriction 3Health News:NewCourtland Network Plans to Transfer Ownership of Five Nursing Homes 2
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Medicine Products: